Prostate Cancer – Henrik Grönberg's research group

Main research area is prostate cancer genetics focusing on identifying new markers both for the risk of getting prostate cancer and for the prognosis of prostate cancer once diagnosed.

Part of the Department of Medical Epidemiology and Biostatistics

The ProBio study

Currently the main focus of the research group is the ProBio study. ProBio is an outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer. 

The lack of treatment-predictive biomarkers is an unmet clinical need in metastatic prostate cancer leading to inferior clinical outcomes, overtreatment and accelerating costs. The ProBio concept builds on a novel adaptive study design and prospectively evaluates treatment predictive biomarker signatures in a large network of 35 study centers in Europe. 

By using the ProBio platform we are able to rapidly evaluate both new and old drugs in subsets of patients with a similar genomic biomarker. The aim is to give patients with metastatic prostate cancer an individualized treatment based on treatment-predictive genomic biomarker signatures in the near future.

STHLM3

STHLM3 was a large-scale prospective and population-based prostate cancer diagnostic trial involving close to 60, 000 men in Stockholm 2013-2015 with the aim of to develop and validate a model to identify high-risk prostate cancer with better test characteristics. Two screening methods, PSA and the Stockholm3 test, were assessed and compared for safety and efficacy. 

The primary aim of the STHLM3 trial was to investigate if the Stockholm3 test could substantially reduce the proportion of men undergoing prostate biopsy whilst maintaining the sensitivity for detecting consequential prostate cancer (Gleason Score 7 or above) compared to PSA. 

The results showed that the Stockholm3 test could reduce the number of unnecessary prostate biopsies by close to 50% and decrease indolent cancers (Gleason 6, typically regarded as overdiagnosed cancers) by 20%, without reducing the sensitivity to detect consequential prostate cancer compared to using the PSA. 

The data from the trial provides a fantastic resource for studying prostate cancer diagnostics, and has since the publication of the main results in the Lancet Oncology 2015 been used in a large number of follow-up publications.

The Stockholm3 test

The Stockholm3 test is a blood test developed in the research group that combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at an early stage.

Publications

All publications from group members

Staff and contact

Group leader

All members of the group

Visiting address

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Nobels väg 12A, Stockholm, 17177, Sweden

Postal address

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, PO Box 281, Stockholm, 17177, Sweden

ProBio International Investigator's meeting

The second ProBio International Investigator's Meeting in Stockholm will be held at Elite Hotel Marina Tower in Stockholm on October 7-8. 

09:00-17:00
Preliminary agenda

Overview and update of the ProBio study

Scientific results from ProBio:

  • ARPi vs taxanes in mCRPC
  • Quality of life ARPi vs taxanes in mCRPC
  • Carboplatin in mCRPC
  • Survival in ctDNA negative patients
  • PSA trajectory

Presentations from patient organisations

Scientific presentations of experimental compounds:

  • Niraparib/AAP – Janssen
  • Capivasertib – AstraZeneca
  • Darolutamide – Bayer

Result of the inclusion competition

09:00-14:00
Preliminary agenda

Break-out sessions:

  • Study nurses and coordinators – training and discussion
  • Physicians – in depth discussion of results and future prospects

Update to version 6.0 of the protocol

Opening new arm Darolutamide monotherapy

PSMA-PET in metastatic prostate cancer

Clinical implementation of BRCA testing in Sweden

Future development of ProBio

Contact and questions